Antipsychotic Induced Weight Gain

Download PDF

Antipsychotics are used to treat several mental health conditions including schizophrenia, bipolar disorder, and psychosis. These medications can have less side effects but can lead to weight gain.
  1. DeJongh BM. Clinical pearls for the monitoring and treatment of antipsychotic induced metabolic syndrome. Ment Health Clin. 2021 Nov 1;11(6):311-319. American Association of Psychiatric Pharmacists (AAPP); 2021 Nov 1. DOI: 10.9740/mhc.2021.11.311.
  2. Dayabandara M, Hanwella R, Ratnatunga S, Seneviratne S, Suraweera C, de Silva V. Antipsychotic-associated weight gain: management strategies and impact on treatment adherence. NDT. 2017 Aug;Volume 13:2231-2241. Informa UK Limited; 2017 Aug. DOI: 10.2147/ndt.s113099.
  3. Fitzgerald I, O'Connell J, Keating D, Hynes C, McWilliams S, Crowley EK. Metformin in the management of antipsychotic-induced weight gain in adults with psychosis: development of the first evidence-based guideline using GRADE methodology. Evid Based Ment Health. 2022 Feb;25(1):15-22. BMJ; 2022 Feb. DOI: 10.1136/ebmental-2021-300291.
  4. McClellan J, Stock S. Practice Parameter for the Assessment and Treatment of Children and Adolescents With Schizophrenia. J Am Acad Child & Adolesc Psychiatry. 2013 Sep;52(9):976-990. Elsevier BV; 2013 Sep. DOI: 10.1016/j.jaac.2013.02.008.
  5. Consensus Development Conference on Antipsychotic Drugs and Obesity and Diabetes. Diabetes Care. 2004 Feb 1;27(2):596-601. American Diabetes Association; 2004 Feb 1. DOI: 10.2337/diacare.27.2.596.
  6. Baerlocher MO, Asch M, Myers A. Metformin and intravenous contrast. CMAJ. 2013 Jan 8;185(1):E78-E78. CMA Impact Inc.; 2013 Jan 8. DOI: 10.1503/cmaj.090550.
  7. Topiramate. 2017. Janssen Pharmaceuticals, Inc.; 2017.
  8. Semaglutide Treatment On Coronary Progression. CMR. 2019 Jun 13. Case Journals; 2019 Jun 13. DOI: 10.31525/ct1-nct03985384.
  9. Knop FK, Aroda VR, do Vale RD, Holst-Hansen T, Laursen PN, Rosenstock J, et al. Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023 Aug;402(10403):705-719. Elsevier BV; 2023 Aug. DOI: 10.1016/s0140-6736(23)01185-6.
  10. Liraglutide. 2018. Novo Nordisk Inc.; 2018.